Unjha Formul.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE576D01015
NSEID:
BSEID: 531762
View on BSE

INR

22.95

-0.11 (-0.48%)

BSENSE

Feb 06

BSE+NSE Vol: 1.19 k

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Colinz Labs

Beryl Drugs

Unjha Formul.

Vivanza Biosci.

Adline Chem Lab

Parmax Pharma

Decipher Labs

Starsource Multi

Ortin Global

Genomic Valley

Saroja Pharma In

Why is Unjha Formulations Ltd ?

Weak Long Term Fundamental Strength with a 15.77% CAGR growth in Operating Profits over the last 5 years

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.54

Flat results in Dec 25

Underperformed the market in the last 1 year

Even though the market (BSE500) has generated returns of 7.71% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -17.92% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Unjha Formul. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Unjha Formul.

-17.92%

-0.30

59.75%

Sensex

7.07%

0.61

11.53%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.33%

EBIT Growth (5y)

15.77%

EBIT to Interest (avg)

0.54

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-0.20

Sales to Capital Employed (avg)

5.42

Tax Ratio

10.34%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

13.11%

ROE (avg)

10.35%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.27

EV to EBIT

9.64

EV to EBITDA

8.69

EV to Capital Employed

3.86

EV to Sales

0.66

PEG Ratio

0.15

Dividend Yield

ROCE (Latest)

16.80%

ROE (Latest)

33.12%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

PAT(Latest six months)

Higher at Rs 1.06 cr

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Loading Valuation Snapshot...

Here's what is working for Unjha Formul.

Profit After Tax (PAT) - Latest six months

Higher at Rs 1.06 cr

than preceding 12 month period ended Dec 2025 of Rs 0.09 cr

MOJO Watch

In the half year the company has already crossed PAT of the previous twelve months

PAT (Rs Cr)